
Ionis Pharma (IONS) Stock Forecast & Price Target
Ionis Pharma (IONS) Analyst Ratings
Bulls say
Ionis Pharmaceuticals is attractive because its antisense platform has already produced multiple approved drugs, including Spinraza, Qalsody, Wainua, Tryngolza, Dawnzera, Tegsedi, and Waylivra, validating both the science and its ability to convert R&D into recurring royalty and product revenue. The company also has a broad wholly owned and partnered pipeline in cardiometabolic, neurological, and rare diseases, with several positive readouts expected in FY27 and additional partnered programs like Hibsago, sefaxersen, and ulefnersen that can add milestone and royalty upside. Commercial momentum looks underappreciated: Dawnzera generated $37M in Q3 sales, Spinraza royalties reached $69M versus $55M consensus, and Tryngolza still carries blockbuster potential despite a moderate launch, supporting a favorable long-term fundamental view.
Bears say
Ionis Pharmaceuticals is facing a weaker fundamental setup because Tryngolza’s launch is materially underperforming, with Q3 sales of about $9M versus $20M-$21M expected and management cutting FY26 guidance to roughly $50M from $100M-$110M, while only about 1,500 HCPs have prescribed and just 24% have written more than one script. The slow ramp reflects limited formulary coverage, heavy reliance on free drug through Quick Start, step-edit barriers, and cautious physician adoption, which together push the path to broader monetization and the >$3B peak-sales narrative much further out. At the same time, Wainua royalties are moderating, obudanersen’s probability of success was cut to 35% after ASPIRE, and cash-flow break-even has been pushed to 2029, increasing execution and financing risk despite a still-strong $1.884B cash balance.
This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Ionis Pharma (IONS) Analyst Forecast & Price Prediction
Start investing in Ionis Pharma (IONS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ionis Pharma (IONS) Forecast
Ionis Pharma (IONS) Analyst Forecast & Price Prediction
Start investing in Ionis Pharma (IONS)
Order type
Buy in
Order amount
Est. shares
0 shares